Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 8/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464268 | 0.93 | KDM4E (0.53) | KDM4EMAPTGAAL3MBTL1ALDH1A1 | |
| SCHEMBL13983151 | 0.83 | TDP1 (0.59) | KDM4EMAPTGAAL3MBTL1ALDH1A1 | |
| SCHEMBL13983414 | 0.81 | HSP90AA1 (0.62) | KDM4EMAPTGAAL3MBTL1ALDH1A1 | |
| SCHEMBL10072740 | 0.80 | HSP90AA1 (0.46) | KDM4EMAPTGAAL3MBTL1ALDH1A1 | |
| SCHEMBL13983483 | 0.79 | KDM4E (0.48) | KDM4EMAPTGAAL3MBTL1ALDH1A1 | |
| SCHEMBL13983088 | 0.78 | HSP90AA1 (0.53) | KDM4EMAPTGAAL3MBTL1ALDH1A1 | |
| SCHEMBL13983420 | 0.78 | HSP90AA1 (0.64) | KDM4EMAPTGAAL3MBTL1ALDH1A1 | |
| SCHEMBL13983479 | 0.78 | HSP90AA1 (0.60) | KDM4EMAPTGAAL3MBTL1ALDH1A1 | |
| SCHEMBL13983103 | 0.77 | ALDH1A1 (0.48) | KDM4EMAPTGAAL3MBTL1ALDH1A1 | |
| SCHEMBL13983080 | 0.77 | HSP90AA1 (0.64) | KDM4EMAPTGAAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013170159-A1 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013074594-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH BRAF INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013067162-A1 | CANCER THERAPY USING A COMBINATION OF HSP90 INHIBITORS WITH TOPOISOMERASE I INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067165-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013006864-A2 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012162372-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MTOR/P13K INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162584-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162293-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MEK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012096919-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH PROTEASOME INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2011149824-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011146803-A1 | METHOD OF TREATING LUNG ADENOCARCINOMA WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011133521-A2 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A VEGF INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133520-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2008153730-A2 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | SYNTA PHARMACEUTICALS CORP. (US) | 2008-12-18 | — | — | WO | disclosed |